单独针对血管新生,并与免疫检查点抑制剂组合用于晚期胃食道恶性瘤
Alireza Tojjari1, Robin Park2, James Yu2
1Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, 15213, USA.
Current gastroenterology reports
|January 31, 2024
概括
用抑制剂向血管生成,并将它们与免疫检查点抑制剂 (ICI) 结合起来,对晚期胃食道癌症有很大的前景. 这种方法改善了有限选择的患者的生存结果和反应率.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 翻译医学是一种翻译医学.
背景情况:
- 先进的胃食道恶性瘤带来了重大的治疗挑战.
- 传统化疗在晚期疾病阶段的疗效有限.
- 血管新生是瘤生长和进展的关键途径.
研究的目的:
- 审查目前针对晚期胃食道癌症的治疗策略.
- 为了评估血管新生作为治疗目标.
- 探索血管新生抑制剂和免疫检查点抑制剂 (ICI) 的组合.
主要方法:
- 对最近的临床试验和新出现的证据进行批判性审查.
- 对VEGFR通路抑制剂 (例如,雷戈拉费尼布,阿帕蒂尼布,苏尼提尼布) 的数据分析.
- 检查涉及与ICI结合治疗的研究.
主要成果:
- 在无进展生存期 (PFS) 和整体生存期 (OS) 中,VEGFR路径抑制剂显示出显著的益处.
- 像INTEGRATE IIa这样的临床试验强调了向治疗的有效性.
- 结合治疗与ICI显示在晚期胃食道癌症中反应率增加.
结论:
- 针对血管生成是晚期胃食道恶性瘤的关键策略.
- 将血管新生抑制剂与ICI结合起来,提供了一个有前途的治疗方法.
- 治疗领域正在向向治疗和免疫治疗转变,以改善患者的治疗结果.
更多相关视频
相关概念视频
Tumor Immunotherapy
526
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
526
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Mechanism of Angiogenesis
5.5K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.5K
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K


